Amgen Inc. Operating Lease, Weighted Average Discount Rate, Percent
Amgen Inc. (AMGN) had Operating Lease, Weighted Average Discount Rate, Percent of 4.00% as of 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-02-13
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 4.00%.
- 2024-12-31: Operating Lease, Weighted Average Discount Rate, Percent 3.70%.
- 2023-12-31: Operating Lease, Weighted Average Discount Rate, Percent 3.60%.
- 2022-12-31: Operating Lease, Weighted Average Discount Rate, Percent 2.70%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent |
|---|---|
| 2025-12-31 | 4.00% 10-K · filed 2026-02-13 |
| 2024-12-31 | 3.70% 10-K · filed 2026-02-13 |
| 2023-12-31 | 3.60% 10-K · filed 2025-02-14 |
| 2022-12-31 | 2.70% 10-K · filed 2024-02-14 |
| 2021-12-31 | 2.50% 10-K · filed 2023-02-09 |
| 2020-12-31 | 3.10% 10-K · filed 2022-02-16 |
| 2019-12-31 | 3.30% 10-K · filed 2021-02-09 |
| 2019-09-30 | 3.31% 10-Q · filed 2019-10-30 |
| 2019-06-30 | 3.32% 10-Q · filed 2019-07-31 |
| 2019-03-31 | 3.32% 10-Q · filed 2019-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |